GIBSON DUNN

Gibson Dunn Advises BVF Partners L.P. on up to $400 Million Financing for Immunic, Inc.

Firm News | February 25, 2026

Gibson Dunn represented BVF Partners L.P. as lead investor in the up to $400 million private placement financing for Immunic, Inc., a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases.

Gibson Dunn regularly advises life sciences investors on large-scale private placement financings for biotechnology companies.

The Gibson Dunn team included Ryan Murr, Branden Berns, Karen Spindler, Nick Linke, and Lauren Romagnoli.

Related People

Ryan A. Murr

Branden C. Berns

Karen A. Spindler

Nicholas G. Linke

Lauren Romagnoli

Related Capabilities

Life Sciences

Finance

Private Equity

Emerging Companies / Venture Capital

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**